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Hypertension is a disorder prevalent in adults around the world and is a 
common attributable cause of heart disease and mortality [1]. Calcification is 
much more common in the aortic valve than the other three heart valves [2]. 
Aortic valve interstitial cells (VICs), the principal cell type found in the human 
aortic valve, have been linked to disease development when they change in 
phenotype to become osteoblast like cells [3]. The phenotypes of these cells play 
a role in the development of calcification in the aortic valves [4]. 
Angiotensin II is a hormone in the body that has been implicated to 
stimulate inflammation in heart valves and is linked to the development of heart 
valve disease [5][6]. Losartan (AT1R antagonist) and PD123319 (AT2R 
antagonist) are commercially available drugs to prevent ang-II from binding to 
ang-II receptors on the cells [7][8]. There are certain protein signatures (RUNX2, 
αSMA, Ki-67, TGFβ1, Vimentin, and Calponin) that can be observed to 
determine if VICs are being activated in the presence of ang-I or ang-II with and 
without the presence of receptor antagonists. 
 Cells were cultured in 10% media with six treatment groups and one 
control: angiotensin I (ang-I) without an inhibitor, angiotensin II (ang-II) without an 
inhibitor, angiotensin I + Losartan (ang-I + Los), angiotensin II + Losartan (ang -I 
+ Los), angiotensin I + PD123319 (ang-I + PD), and angiotensin II + PD123319 
(ang-II + PD). Expression of protein signatures was assessed using 
immunocytochemistry. Results displayed phenotypic change in the form of 
increased expression of protein signatures in VICs with treatment groups. Most 
VICs were inhibited in the presence of losartan, demonstrating that the binding of 






The heart is a vital organ that is needed for survival [9]. It consists of four 
chambers: the right and left atria and the right and left ventricle, and four valves: 
the tricuspid, pulmonary, mitral, and aortic. The aortic valve is what enables 
freshly oxygenated blood to flow from the left ventricle to the aorta and on to the 
body’s systemic circulation [9].  
 
 
Figure 1: Image illustrating flood flow through heart [10] 
 
Aortic valve calcification occurs when calcium deposits form on the aortic valve, 
causing a narrowing in the opening of the valve that reduces blood flow. When 
flow is restricted, it results in aortic valve stenosis. This is a common early sign of 




Figure 2: Healthy and aortic and aortic valve stenosis visualization [12] 
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Calcification of the aortic valve is much more common than calcification of the 
other three heart valves. Calcific aortic stenosis is the 3rd most prevalent 
cardiovascular disease in the United States [2]. Valvular aortic stenosis caused 
by calcification of cells is commonly associated with hypertension, a disease that 
affects 2% of the population above the age of 65 [13].  
 
Aortic valve interstitial cells (VICs), the principal cell type found in the human 
aortic valve, have been linked to disease development when they change in 
phenotype to become osteoblast-like cells [3]. The phenotypes of these cells play 
a role in the development of calcification in the aortic valves [4]. The calcification 
of aortic valves is not due to random degeneration, but rather an active process 
of bone formation in the aortic valve associated with certain cell phenotypes [14]. 
VIC phenotypes include quiescent (qVICs), activated (aVICs), and osteoblastic 
(obVICs). Quiescent VICs are responsible for maintaining normal valve functions, 
and are normally inactive. If the cells are injured or stressed, they have a 
tendency to become aVICs, which can easily differentiate into diseased obVICs 
[15]. Active VICs are a very important part of the wound repair process, and are 
usually eliminated by apoptosis once they have served their purpose. If this 
apoptosis fails it may result in pathological fibrosis, chronic inflammation, and 




Figure 3: Illustration of how Valve Interstitial Cells can go from quiescent, to activated, 
and then osteoblastic/diseased 
 
Angiotensin II (ang-II) is a hormone in the body partially responsible for 
regulating blood pressure, cardiac function, and plasma volume. It’s of incredible 
importance in hypertension and is a fundamental effector of the renin-angiotensin 
system [6][16]. Studies have shown that ang-II has been implicated to stimulate 
inflammation in heart valves and is linked to the development of heart valve 
disease [5][6]. Angiotensin receptor blockers are among some of the only 
standard evidence-based heart failure therapies [13]. All national guidelines 
recommend an angiotensin receptor blocker as a part of anti-hypertension 
therapy [1]. Recently, there has been clinical evidence that long-term blocking of 
ang-II conversion could have a protective effect against carcinogenesis [6]. 
 
Renin is an enzyme produced by the kidneys and acts on the protein 
angiotensinogen that’s formed by the liver to produce the hormone Angiotensin I 
(ang-I). Ang-I can be transformed into ang-II in the blood via the angiotensin-
converting enzyme (ACE). This is commonly referred to as the renin-angiotensin 
System, or RAS [17]. Ang-II (ang-I) can then bind to two different ang-II receptors 
on cells that mediate the majority of its effects, angiotensin II type 1 receptor 









There are currently four classes of medications that focus on various aspects of 
the renin-angiotensin system pathway in an effort to combat hypertension. These 
include angiotensin converting enzyme (ACE) inhibitors, aldosterone antagonists, 
direct renin inhibitors, and ang-II receptor blockers (ARBs) [1]. The two ARBs 
that will be utilized in this experiment are Losartan and PD123319. In general, 
ARBs are better tolerated and produce fewer side effects than ACE inhibitors 
[18]. Unfortunately, ACE inhibitors are only partially successful in inhibiting the 
formation of ang-II, and are related to several adverse effects such as chronic 
cough and angioedema [1][18].  
 
Losartan (AT1R antagonist) and PD123319 (AT2R antagonist) are commercially 
available drugs to prevent ang-II from binding to ang-II receptors on the cells 
[7][8]. AT2R expression is increased in tissues experiencing hypertension, 
cardiac hypertrophy, and ischemic heart disease. AT2R negatively regulates 
AT1R signaling, but the precise mechanism that makes this happen is poorly 
understood [19]. AT1R activates growth-promoting pathways and mediates ang-II 
effects such as vasoconstriction and increased blood pressure as well as 
detrimental effects such as inflammation. AT2R has been linked to producing 
opposite effects, such as vasodilation, hypotension, and possible inhibition of 




Figure 4: Illustration of ang-I to ang-II pathway with AT1R and AT2R inhibiting medications 
 
There are certain protein signatures that can be observed to determine if VICs 
are being activated in the presence of ang-I or ang-II with and without the 
presence of receptor antagonists. If the marker Vimentin were up regulated, it 
would indicate more quiescent VICs [24]. If the markers αSMA, Ki-67, TGFβ1, 
and Calponin are up regulated, it’s an indicator of increased aVICs. 
[5][21][20][15][22][23]. These aVICs can easily differentiate into obVICs, which 
regulate osteogenesis and the calcification process [15]. ObVICs secrete 
RUNX2, so if this marker is present in the sample cells are likely to be calcified 
[14][15]. It is important to look for these markers in to test whether the VICs are 











Table 1: Table simplifying protein signature markers, their roles in the body, and what an up-
regulation in results would indicate. Sources: [5][21][20][15] [22][23][24][14] 
Marker Role in the Body Up-regulation would 
mean  
RUNX2 Transcription factor necessary for 
bone formation 
More osteogenic VICs 
αSMA Smooth muscle actin, Marker for 
aVIC activation 
More activated VICs  
Ki-67 Protein with important function in 
cell division 
More activated VICs  
TGFβ1  Growth factor secreted by aVICs, 
also increases overexpression of 
αSMA 
More activated VICs 
Vimentin Proteins expressed in inactive 
VICs 
More quiescent VICs 
Calponin Protein shown to regulate 
smooth muscle cell differentiation 
More activated VICs  
 
 
Objectives and Hypothesis  
 
The objective of this research was to better understand how the renin-
angiotensin system affected the phenotype of valve interstitial cells both with and 
without the presence of inhibitors.  
 
There are two main questions we were hoping to answer: 
1. Are VICs changing in phenotype in the presence of ang-I and ang-II?  
2. Is RAS affecting the phenotype of VICs due to the binding of ang-II to AT1R or 
AT2R?  
 
We hypothesized that the renin-angiotensin system will alter the phenotype of 
VICs. Additionally, we hypothesized that VICs will become more osteogenic in 
the presence of ang-II and will experience up-regulation in markers for aVICs and 





To prepare 2% media for coverslips  
In order to make 500mL of media total, 2% needs to be FBS, 1% needs to be 
Penicillin Streptomycin, 1% needs to be HEPES, and the rest should consist of 
DMEM media. In order to accomplish this, 10mL of 2% FBS, 5mL of Penicillin 
Streptomycin, and 5mL of HEPES was added to 480mL of DMEM media.  
 
To prepare 10% media for culture in the flask 
In order to make 500mL of media total, 10% needs to be 2%FBS, 1% needs to 
be Penicillin Streptomycin, 1% needs to be HEPES, and the rest should consist 
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of DMEM media. In order to accomplish this, 50mL of 2% FBS, 5mL of Penicillin 
Streptomycin, and 5mL of HEPES was added to 440mL of DMEM media.  
 
The entire 500mL media mixture was run through a filter, using an aspirator as a 
vacuum.  
 
Sterilizing cover slips  
18mm diameter cover slips were autoclaved for one hour. 
 
Cell Culture and Seeding 
A T175 flask confluent with porcine valvular interstitial cells from an aortic valve 
growing in 10% media was prepared in advance. All cell culture was performed in 
a biosafety cabinet, and all outside materials were sterilized with 70% ethanol 
before entering the sterile environment. 100µL of gelatin was placed onto each 
autoclaved coverslip and incubated at 37 degrees Celsius and 5% CO2 for one 
hour. Seven 12 well plates were set out, and 1mL of PBS was pipetted into each 
well. A coverslip was placed in each well, with the gelatin side face up. The PBS 
was aspirated from the wells are replaced three times to wash the coverslips. 
2mL of .25% trypsin was pipetted into the confluent T175 flask and left to 
incubate for 2 minutes. The T175 flask was removed from the incubator and 
tapped firmly against the inside of a wrist to loosen the cells from the bottom of 
the flask. Cells were observed under a microscope while still in the T175 flask to 
ensure that they were visibly unstuck/ appeared more round than their adhered 
fibroblast-like state. 15mL of 10% red media was pipetted into the T175 flask and 
swirled around to cover the surface area of the flask several times to deactivate 
the trypsin. All media was then pipetted out of the T175 flask and into a 50mL 
centrifuge tube. The 50mL tube was centrifuged at 4 degrees Celsius for 6 
minutes. The supernatant was removed and discarded by bleaching and placing 
it in biohazard waste. 3mL of 2% media was pipetted into the 50mL tube 
containing the pellet and mixed thoroughly until the pellet was dissolved.  
 
Cell counting took place with a hemocytometer. 20µL of well-mixed sample was 
transferred into a small eppendorf tube to take to the microscope. 10µL of 
sample was pipetted into each side of the hemocytometer, and cells were 
counted in the center and averaged to estimate the density of the sample. 161 
cells were counted on one side and 80 cells were counted on the second side. 
This averaged out to be about 119.5 ∗ 10! cells per mL of solution. Accounting for 
the 3mL of media that the pellet was suspended in, centrifuge tube was 
estimated to have about 3.59 ∗ 10! cells in the suspension. Each of the 84 
coverslips needed to be seeded with 2,000 cells, so it was calculated that 







84 𝑐𝑜𝑣𝑒𝑟 𝑠𝑙𝑖𝑝𝑠 ∗ 2,000 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑠𝑙𝑖𝑝 = 168,000 𝑐𝑒𝑙𝑙𝑠 𝑛𝑒𝑒𝑑𝑒𝑑 
 




 was used 
to calculate the second volume number to extract the amount of cells desired. It 
was calculated that 167µL of the mixture was needed from the 50mL centrifuge 
tube to obtain the approximate amount of cells for the current procedure. It was 
then calculated that 8.233mL of media from the 167µL would be needed for 
seeding cells onto coverslips.  
𝑣𝑜𝑙𝑢𝑚𝑒 2 = !.!∗!"
! ∗ !!!
!.!" ∗ !"!
 = 167µL 
 
84 𝑐𝑜𝑣𝑒𝑟 𝑠𝑙𝑖𝑝𝑠 ∗ 100µL of cell solution = 8.4mL 
 
8.4𝑚𝐿 − 0.167𝑚𝐿 = 8.233𝑚𝐿 𝑜𝑓 𝑚𝑒𝑑𝑖𝑎 𝑓𝑟𝑜𝑚 167µL cell solution 
 
100µL of cell solution was pipetted onto the prepared gelatin coverslips, being 
careful not to break the surface tension of the media so that all cells would 





Each of the seven 12 well plates were labeled with the date (4/3/18), the name of 
the cell line (VIC5), the passage number (P5), who was the primary handler for 
each plate, and the treatment group. There was one treatment group for each 12 
well plate: control, angiotensin I (ang-I) without an inhibitor, angiotensin II (ang-II) 
without an inhibitor, angiotensin I + Losartan (ang-I + Los), angiotensin II + 
Losartan (ang-II + Los), angiotensin I + PD123319 (ang-I + PD), and angiotensin 
II + PD123319 (ang-II + PD).  
 
Coverslips were treated with respective inhibitors (Losartan or PD123319) for 24 
hours while the control and other non-inhibitor groups incubated in 2% media. 
Afterwards, coverslips were treated with ang-I (10!!) or ang-II (10!!) for 2 days. 
The cells had a total of 5 days on the coverslips before fixing.  
 
12.375mL of 2% media and 125µL of Losartan (10!!) was added into the 15mL 
“Los” tube. 12.375mL of 2% media and 125µL of PD123319 (10!!) was added 
into the 15mL “PD” tube. Each 15mL tube was vortexed and placed in a water 
bath. 500µL of fluid from the “Los” tube was applied to each treatment group well 
that was labeled with Losartan, 24 wells in total. 500µL of fluid from the “PD” tube 
was applied to each treatment group well that was labeled with PD123319, 24 
wells in total. Cover slips were ensured to be completely submerged in their 
respective solutions before returning them to the incubator overnight. This was 






Fixing the slides 
All materials were brought to room temperature before the process began. Cells 
were transported from the incubator to the fume hood and were rinsed gently 3x 
in PBS. After the third wash, the PBS was aspirated from the plate wells. Each 
coverslip was stained using 400µL of a 4% Paraformaldehyde (PFA), Triton-X 
100, and PBS stock solution mixture in a dark fumigated environment for 10 
minutes. All waste solution was aspirated and disposed of in container labeled as 
“toxic”. Immediately, 3-4mL of PBS was added to each coverslip well, swirled 
gently to rinse, and left to sit for 10 minutes. This process of rinsing with PBS 
was repeated two more times. After the final wash, the coverslips were left to sit 
in PBS at 4 degrees Celsius for the night.  
 
Blocking 
PBS was aspirated from the coverslip wells and 130µL per well of 10% goat 
serum (the species of the secondary antibody) was pipetted onto the coverslips 
and left to incubate at 37 degrees Celsius for 60 minutes.  
 
Primary Stain 
This was done in a light-protected environment. Primary antibody solution was 
prepared in advance, and consisted of 1% goat serum (Abcam), the designated 
concentration of the marker for the respective treatment group, and PBS. 









RUNX2 (1/200) Rabbit 
αSMA (1/100) Mouse 
Ki-67 (1/200) Rabbit 
TGFβ1 (1/100) Rabbit 
Vimentin (1/200) Mouse 
Calponin (1/200) Rabbit 
 
Seven 130µL drops (one for each coverslip treatment group) were placed into 
eight different clean Petri dishes (one for each treatment group and a negative 
control) evenly spaced out. Using forceps, coverslips were placed over the 
solution cell-side down and left to incubate at 4 degrees Celsius overnight. After 
the incubation period, coverslips were placed into 12-well plates cell-side up and 
left to sit in PBS for 10 minutes, then washed gently with PBS two more times. 
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For each coverslip, 130µL of secondary stain was prepared. The secondary stain 
consisted of 1:200 DAPI stock, 1% Goat serum, 1:200 of the appropriate 
secondary antibody (goat or rabbit, Abcam) Alexa Fluor 594 conjugate, and PBS. 
If a mouse primary antibody was used, a goat-anti-mouse IgG was used for the 
secondary antibody. If a rabbit primary antibody was used, a goat-anti-rabbit IgG 
was used for the secondary antibody. All components of the secondary stain 
were mixed well with a vortex and protected from light. In addition to previously 
treated coverslips, seven untreated coverslips from each treatment group were 
also stained with secondary antibody to serve as a negative control.  
 
Coverslips were incubated in the secondary stain for 1 hour and 45 minutes in 
the dark. After the incubation period, coverslips were rinsed gently in PBS for 
10minutes, then the PBS was aspirated and the slips were washed 3 more times 
in PBS, leaving the last round of PBS sitting on the coverslips until mounting 




One glass slide was prepared for every coverslip, fitting two coverslips per slide. 
Slides were labeled with n1 or n2, the primary antibody, the date of fixing, the 
name of the primary handler, and the treatment group. A drop of prolong gold 
anti-fade reagent (Invitrogen #P36930) without any bubbles was placed onto the 
clean slides, then the coverslips were carefully placed cell-side down into it. All 
slides were laid flat in a dark environment to dry overnight, then placed in a slide 




Cells were imaged with a standard epifluorescence microscope at 20x for both 
DAPI and red 594. Four to five images were taken of each coverslip for both 
DAPI and red 594, for a total of 8-10 pictures per coverslip. Select images were 
compiled together for visual quantitative analysis. ImageJ was used to compile 









Results and Discussion: 
 
RUNX2: Increased expression in ang-I and ang-II treatment groups in 
comparison to the control indicating cells became more osteogenic. In the 
presence of PD123319 there was less expression than in the presence of 
losartan indicating AT2R receptors were blocked more.  
 
 




αSMA: Increased in expression for ang-I & ang-II with no inhibitors, indicating 
cells became more activated. In the presence of PD123319 there was more 
expression than in the presence of Losartan, indicating blocking the AT1R 
receptor had more of an effect suppressing this marker. 
 
 




Ki-67: Increased in expression for ang-I & ang-II, indicating cells became more 
activated. In the presence of PD123319 there was more expression than in the 
presence of losartan, indicating blocking the AT1R receptor had more of an effect 
suppressing this marker. 
 
 





TGFβ1: Increased in expression for ang-I & ang-II, indicating cells became more 
activated. In the presence of PD123319 & losartan there was also increased 
expression, indicating blocking AT1R & AT2R receptors had no effect on this 
marker for this particular incubation time. 
 
 





Vimentin: Increased in expression for ang-I & ang-II, indicating cells were more 
quiescent VICs, which was an unexpected result. Interestingly enough, this 
expression was equally vibrant for both ang-I and ang-II samples, indicating a 
potential conversion of ang-I samples to ang-II.  
 







Calponin: Increased in expression for ang-I and especially for ang-II, indicating 
cells became more activated. In the presence of PD123319 and losartan there 
was little expression in comparison, indicating AT1R & AT2R receptors were 
blocked. 
 





Negative control: No expression/ non-specific binding of the secondary reagent, 
indicating no contamination of samples.  
 
 
Figure 11. Immunocytochemistry images of Negative Control expression of the 7 treatment 





Conclusions, Limitations, and Future Directions: 
 
Results displayed phenotypic changes in the form of increased expression of 
protein signatures in VICs with ang-I and ang-II treatment groups when 
compared with their respective controls. Most VICs were inhibited in the 
presence of losartan, demonstrating that the binding of ang-II to AT1R is causing 
increased activation of the VICs. If ang-II is still having the same effect it does in 
the presence of PD123319 as it does in the presence of Losartan, then AT2R 
must not be the receptor responsible for the phenotypic changes. It’s likely that 
AT2R binding isn’t making as big of an impact on the phenotype of VICs in 
comparison to binding to AT1R. To further verify this, future work should perform 
more quantitative analysis over multiple time periods.  
 
Limitations of the procedure were not enough cells used while seeding to be able 
to do quantitative analysis. Cells were seeded sparsely intentionally to avoid 
activating them with a high density, but the density of cells should be increased 
when repeating this procedure. In the future, quantitative analysis will be done in 
more confluent samples, and western blots will be conducted to further confirm 
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